Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

FDA approves venetoclax for chronic lymphocytic leukaemia and small lymphocytic lymphoma

The Food and Drug Administration (FDA) approved venetoclax for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

Approval was based on CLL14 (NCT02242942), a randomised (1:1), multi-centre open label, actively controlled trial of venetoclax in combination with obinutuzumab (VEN G) versus obinutuzumab in combination with chlorambucil (GClb) in 432 patients with previously untreated CLL with coexisting medical conditions.

The major efficacy outcome was progression-free survival (PFS) assessed by an independent review committee.

The trial demonstrated a statistically significant improvement in PFS for patients who received VEN G compared with those who received GClb (HR 0.33; 95% CI: 0.22, 0.51; p<0.0001).

Median PFS was not reached in either arm after a median follow-up duration of 28 months.

The overall response rate was 85 percent in VEN G arm compared to 71 percent in GClb arm, p=0.0007.

The trial also demonstrated statistically significant improvements in rates of minimal residual disease negativity (less than one CLL cell per 104 leukocytes) in bone marrow and peripheral blood.

Overall survival data were not mature at this analysis.

In CLL/SLL, the most common adverse reactions (≥ 20 percent) for venetoclax when administered with obinutuzumab, rituximab, or as monotherapy were neutropenia, thrombocytopenia, anaemia, diarrhoea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, and oedema.

Source: The Food and Drug Administration (FDA)

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation